TNFRSF9 and neoplasm: Increasing the survival of viral-specific or tumor-specific T cells, e.g., by preventing PD-1 signaling or increasing 4-1BB (CD137) signaling [410], should lead to increased anti-viral and anti-tumor immune responses.